General
Preferred name
EDROPHONIUM
Synonyms
EDROPHONIUM CHLORIDE ()
Edrophonium (chloride) ()
Chlorure d'edrophonium ()
Camsilon ()
Reversol ()
Edrophonium Chloride Preservative Free ()
NSC-759577 ()
Tensilon ()
Antirex ()
Edrophonii chloridum ()
Edrophonium chloride component of enlon-plus ()
Cloruro de edrofonio ()
Enlon ()
Tensilon Preservative Free ()
ENLON-PLUS ()
Edrophonium ion ()
Edrophonium cation ()
Edrophonium-d5 (chloride) ()
P&D ID
PD009595
CAS
116-38-1
312-48-1
Tags
available
drug
Approved by
FDA
First approval
1951
Drug indication
Orthostatic hypotension
Myasthenia gravis
Drug Status
approved
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Edrophonium chloride is a reversible inhibitor of acetylcholinesterase.
PRICE
29
DESCRIPTION
Edrophonium is the parent molecule of the clinically used rapid-onset, short-acting cholinesterase inhibitor edrophonium chloride (PubChem CID 8307).
(GtoPdb)
ROE
Edrophonium is primarily renally excreted with 67% of the dose appearing in the urine.; Hepatic metabolism and biliary excretion have also been demonstrated in animals
DESCRIPTION
Acetylcholinesterase inhibitor
(LOPAC library)
DESCRIPTION
Edrophonium chloride is a reversible Acetylcholinesterase inhibitor which is effective in avoiding the decomposition of the neurotransmitter acetylcholine competitively so that could be commonly used in the diagnosis of myasthenia gravis and other sorts o
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Edrophonium chloride is an acetylcholinesterase (AChE) inhibitor that is known to prevent the breakdown of the neurotransmitter acetylcholine by binding specifically to its catalytic site.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Edrophonium is a reversible Acetylcholinesterase inhibitor which is effective in avoiding the decomposition of the neurotransmitter acetylcholine competitively so that could be commonly used in the diagnosis of myasthenia gravis and other sorts of disease
(BOC Sciences Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
24
BOC Sciences Bioactive Compounds
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
99
Molecular Weight
166.12
Hydrogen Bond Acceptors
1
Hydrogen Bond Donors
1
Rotatable Bonds
2
Ring Count
1
Aromatic Ring Count
1
cLogP
1.98
TPSA
20.23
Fraction CSP3
0.4
Chiral centers
0.0
Largest ring
6.0
QED
0.67
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Selectivity
Acetylcholinesterase
Target
AChE
ACHE, BCHE
AChR
Cholinesterase (ChE)
Indication
myasthenia gravis
MOA
Acetylcholinesterase inhibitor
Pathway
Neuroscience
Neuronal Signaling
Therapeutic Class
Antidotes
Solubility
DMSO: 31 mg/mL
Source data

